Cargando…

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

Detalles Bibliográficos
Autores principales:	Gangoda, Lahiru, Schenk, Robyn L., Tai, Lin, Szeto, Pacman, Cheung, Jen G., Strasser, Andreas, Lessene, Guillaume, Shackleton, Mark, Herold, Marco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980089/ https://www.ncbi.nlm.nih.gov/pubmed/35379799 http://dx.doi.org/10.1038/s41419-022-04776-y

Ejemplares similares

The pro-survival Bcl-2 family member A1 delays spontaneous and FAS ligand-induced apoptosis of activated neutrophils
por: Schenk, Robyn L., et al.
Publicado: (2020)

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
por: Luo, Ming-Jie, et al.
Publicado: (2020)

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
por: Cragg, Mark S, et al.
Publicado: (2007)

A1/Bfl-1 in leukocyte development and cell death
por: Ottina, Eleonora, et al.
Publicado: (2012)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Last but not least: BFL-1 as an emerging target for anti-cancer therapies
por: Wang, Gaoyuan, et al.
Publicado: (2022)

Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
por: Jenson, Justin M, et al.
Publicado: (2017)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2023)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells
por: Thijssen, Rachel, et al.
Publicado: (2020)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents
por: Barile, Elisa, et al.
Publicado: (2016)

The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
por: Reuland, Steven N., et al.
Publicado: (2011)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

Cortactin enhances exosome secretion without altering cargo
por: Gangoda, Lahiru, et al.
Publicado: (2016)

Role of Extracellular Vesicles in Cell Death and Inflammation
por: Sanwlani, Rahul, et al.
Publicado: (2021)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

Limited choice of natural amino acids as mimetics restricts design of protein lysine methylation studies
por: Weirich, Sara, et al.
Publicado: (2023)

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells
por: Reinhart, Ramona, et al.
Publicado: (2018)

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
por: Koessinger, Anna L., et al.
Publicado: (2022)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1
por: Kim, Min-Kyoung, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cmfsmdeesnsvib4jjmit4q68uc